Fast Track Status

News Fast Track Status

• Antisoma's phase III trial of AS1413 completes patient enrolment

  Antisoma plc announces that the ACCEDE phase III trial of AS1413 (amonafide L-malate) in secondary acute myeloid leukaemia (secondary AML) is now fully enrolled. Data from the trial are expected in the first half of 2011, with filings for marketing authorisations to follow if these are positive. more

• Genzyme’s Alemtuzumab for Treatment of Multiple Sclerosis Granted Fast Track Status by FDA

  Genzyme Corporation announced that its alemtuzumab for multiple sclerosis development program has been granted Fast Track status by the U.S. Food and Drug Administration (FDA). This designation covers patients with relapsing-remitting forms of the disease. The FDA's Fast Track program is designed t more

• Antisoma's AS1413 gains FDA Fast Track status for treatment of secondary acute myeloid leukaemia

  Antisoma plc announced hat the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company's novel DNA intercalator, AS1413 (amonafide L-malate), for the treatment of secondary acute myeloid leukaemia (secondary AML). The FDA's Fast Track programme is designed to facil more

Market studies Fast Track Status

• Allon Therapeutics Inc. (NPC) - Financial and Strategic SWOT Analysis Review

  Allon Therapeutics Inc. (Allon), formerly Neuro Discovery Inc. is a clinical-stage biotechnology company, engaged in the development of the first drugs that impact the progression of neurodegenerative diseases and disorders. The company is focused on developing neuroprotective therapeutic molecules more

Websites Fast Track Status